A Study to Investigate RO7200220 in Combination With Ranibizumab in Diabetic Macular Edema
Status:
Not yet recruiting
Trial end date:
2024-01-15
Target enrollment:
Participant gender:
Summary
Study BP43464 is a phase II, multicenter, randomized, double-masked active
comparator-controlled study designed to assess the efficacy, safety, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of RO7200220 in combination with,
anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with
ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as
the study eye. The duration of the study will be 52 weeks.